Lee Ji Shin, Kim Hyung Seok, Jung Jong Jae, Kim Young Bog, Lee Min Cheol, Park Chang Soo
Department of Pathology, Seonam University, College of Medicine, Namwon, Korea.
Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):289-95. doi: 10.1097/00129039-200212000-00001.
The vascular endothelial growth factor (VEGF) appears to play an important role in tumor angiogenesis. The p53 and HER-2/neu genes have been thought to regulate VEGF expression. Although the most common genetic alterations described in human breast cancer are p53 gene mutations and HER-2/neu gene amplification, there is a paucity of reports concerning a possible association between VEGF expression and p53 and HER-2/neu expression. Ninety-nine invasive ductal carcinoma cases were examined by immunohistochemical studies with anti-VEGF, anti-p53, anti-HER-2/neu, and anti-CD34 antibodies. Computerized image analysis was used to evaluate the microvessel density (MVD). Eighty-eight tumors (88.9%) were classified as being VEGF positive. Twenty-five tumors (25.3%) showed p53 protein expression, while 36 tumors (35.4%) expressed the HER-2/neu protein. The MVD ranged from 22.0 to 197.0, with a median value of 58.5 (65.4 +/- 27.9). The tumors expressing VEGF had a significantly higher MVD than those that did not (P < 0.05). VEGF expression was significantly associated with p53 protein expression (P < 0.01). In double VEGF and p53 immunohistochemical stained sections, the two markers were generally expressed in the same tumor cells. The cancer stage was the only independent prognostic factor of disease-free and overall survival. The authors' results suggest that VEGF expression plays a role in promoting angiogenesis in invasive ductal carcinoma of the breast, and p53 is likely to be involved in regulating VEGF expression.
血管内皮生长因子(VEGF)似乎在肿瘤血管生成中起重要作用。p53和HER-2/neu基因被认为可调节VEGF表达。尽管人类乳腺癌中描述的最常见基因改变是p53基因突变和HER-2/neu基因扩增,但关于VEGF表达与p53和HER-2/neu表达之间可能关联的报道却很少。采用抗VEGF、抗p53、抗HER-2/neu和抗CD34抗体对99例浸润性导管癌病例进行免疫组织化学研究。使用计算机图像分析评估微血管密度(MVD)。88个肿瘤(88.9%)被分类为VEGF阳性。25个肿瘤(25.3%)显示p53蛋白表达,而36个肿瘤(35.4%)表达HER-2/neu蛋白。MVD范围为22.0至197.0,中位数为58.5(65.4±27.9)。表达VEGF的肿瘤MVD显著高于未表达者(P<0.05)。VEGF表达与p53蛋白表达显著相关(P<0.01)。在VEGF和p53双重免疫组织化学染色切片中,这两种标志物通常在同一肿瘤细胞中表达。癌症分期是无病生存期和总生存期的唯一独立预后因素。作者的结果表明,VEGF表达在促进乳腺浸润性导管癌血管生成中起作用,并且p53可能参与调节VEGF表达。